PLB1001

DRUG5 trials

Sponsors

Beijing Pearl Biotechnology Limited Liability Company

Conditions

GlioblastomaGliomaNon-Small Cell Lung CancerNon-small Cell Lung Cancer

Phase 1

First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001

CompletedNCT02896231

Beijing Pearl Biotechnology Limited Liability CompanyNon-Small Cell Lung Cancer

Start: 2016-04-30End: 2019-10-31Updated: 2019-11-22

Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas

CompletedNCT02978261

Beijing Pearl Biotechnology Limited Liability CompanyGlioma

Start: 2016-09-30End: 2018-12-31Updated: 2020-03-04

Phase 2

A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)

CompletedNCT04258033

Beijing Pearl Biotechnology Limited Liability CompanyNon-small Cell Lung Cancer

Start: 2020-01-17End: 2025-06-24Updated: 2026-06-05

A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

Active, not recruitingNCT06105619

Beijing Pearl Biotechnology Limited Liability CompanyGlioblastoma

Start: 2018-10-08End: 2026-12-31Updated: 2026-01-20

Phase 3

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

RecruitingNCT05989542

Beijing Pearl Biotechnology Limited Liability CompanyNon-small Cell Lung Cancer

Start: 2023-10-16End: 2027-09-30Target: 136Updated: 2025-06-29

Related Papers

Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study.

2025-12-062 citations

Efficacy and safety of the vebreltinib in patients with previously treated, secondary glioblastoma/IDH mutant glioblastoma with PTPR<i>Z</i>1-<i>METFU</i>sion <i>GEN</i>e (FUGEN): A randomised, multicentre, open-label, phase II/III trial.

Journal of Clinical Oncology2024-06-013 citations

Efficacy and safety of vebreltinib in patients with advanced NSCLC harboring MET exon 14-skipping: Results of 2.5-year follow-up in KUNPENG.

Journal of Clinical Oncology2024-06-011 citations

Case report: The effect of second-line vebreltinib treatment on a patient with advanced NSCLC harboring the MET exon 14 skipping mutation after tepotinib treatment

Frontiers in Oncology2024-04-193 citations

Abstract CT127: A phase I study of cMET inhibitor bozitinib in patients with advanced NSCLC harboring <i>cMET</i> alterations

Cancer Research2020-08-1516 citations

Abstract 2096: Bozitinib, a highly selective inhibitor of cMet, demonstrates robust activity in gastric, lung, hepatic and pancreatic in vivo models

Cancer Research2017-07-0112 citations

Co-amplification of <i>MET</i> and <i>PIK3CA</i> in NSCLC and data on a PDX mouse model.

Journal of Clinical Oncology2017-05-201 citations